Le Lézard
Classified in: Health

Dr. Emil Chynn Discusses the Chynn Family Foundation History


NEW YORK, Jan. 18, 2018 /PRNewswire/ -- The Chynn Family Foundation became established in 2009 by K. York Chynn, MD, Dr. Emil Chynn's father. He was a retired Attending Radiologist at St. Lukes-Roosevelt Hospital Center and former Division Chief of Neuroradiology. He is also a Clinical Professor of Radiology at Columbia University's College of Physician's & Surgeons. He taught medical students, interns, residents, and fellows for over 20 years.

The third Board Member is Dr. Emil Chynn, MD, FACS, MBA, a graduate of Columbia University, and has become an outstanding ophthalmologist in New York City. He specializes in laser vision correction, especially the newer, more advanced, non-cutting technique known as LASEK. Dr. Chynn is also the owner of Park Avenue LASEK.

The Chynn Family Foundation was supported financially with $1,000,000 of Dr. KY Chynn's estate. This funding became based on the younger Dr. Chynn and his two sisters, Monica and Audrey agreeing to forgo the money as their inheritance. Also, the group used this sum of money instead to fund scholarships, awards, and other enterprises in the areas of education and to promote "filial piety."

Grants Provided By The Chynn Family Foundation

Who Is Emil Chynn?

Dr. Emil Chynn has significantly traveled in Ukraine and currently has a Refractive Fellow, Tetiana Dovzhuk, who is from Kiev. He has also worked at the most significant laser vision correction center in Ukraine for several years. Dr. Dovzhuk has set up a list of speeches for Dr. Chynn to give in Ukraine in Kiev, Kharkov, Sumy, and Liviv in the spring of 2017.

Furthermore, these talks were to groups of ophthalmologists about LASEK, business people who are MBA graduates about how to pursue business opportunities in the United States. Dr. Chynn has his MBA from New York University as well as his MD from Columbia University. Also, graduate students in English took part in these lectures, and other students studying business English about how to further their English studies overseas.

The Chynn Family Foundation will select three lucky people from Ukraine to come to New York City to study as interns for a two month period. Also, the foundation will provide free round-trip airfare and housing for this learning period. Because the interns will not have work status visas, they must be able to support their minor expenses, including food and minimal boarding costs.

Purpose Of The Chynn Family Foundation

The Chynn Family Foundation believes in integrity, being honest and doing what we say. The foundation approaches their work with an open heart and open mind to generate opportunities and admittance for those most in need. Also, the organization trusts in diversity and distinction by valuing and supporting a more just and caring society.

The Chynn Family Foundation is a private philanthropic organization dedicated to enhancing the status of human life. Applications that also enrich the community help people and promote excellence are considered to be of prime significance. The Foundation views its primary function as that of a catalyst. Also, the foundation seeks to be receptive to programs that are innovative, yet aim to create enduring solutions to community demands.

To visit the Chynn Foundation, please click here.

Media Contact:
Eric Blankenship
[email protected]
786-332-6554

 

SOURCE Emil Chynn


These press releases may also interest you

at 09:00
Dental Care Acworth is thrilled to utilize this remarkable innovation and offer patients unbiased, objective and standardized dental care that they know they can trust. The AI solutions Pearl delivers can assist dental...

at 09:00
Tolland Hill Family Dental is thrilled to announce the addition of Dr. Conway Ma to its esteemed team of dental professionals. Tolland Hill Family Dental offers a wide range of services, catering to patients of all ages. From a child's first dental...

at 09:00
Amgen today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1...

at 09:00
Ractigen Therapeutics, a leader in the development of small activating RNA (saRNA) therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application for RAG-01, a...

at 09:00
Arbele, a clinical-stage biotechnology company focused...

at 08:53
Alera Health, a leader in population health management integrating behavioral healthcare, is proud to announce its recognition as one of the Great Employers to Work for in North Carolina by Best Companies Group. The 2024 Great Employers to Work for...



News published on and distributed by: